Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease
- 29 March 2010
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (7), 1211-1222
- https://doi.org/10.1016/j.ejca.2010.02.041
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-upAnnals of Oncology, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Risks and benefits of bisphosphonatesBritish Journal of Cancer, 2008
- Zoledronsäure bei persistierenden isolierten Tumorzellen im Knochenmark bei MammakarzinomDeutsche Medizinische Wochenschrift (1946), 2008
- Meta-analysis of clodronate and breast cancer survivalBritish Journal of Cancer, 2007
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889